Product logins

Find logins to all Clarivate products below.


Physician &Crohn’s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars | Payer Forum | US | 2014

Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market consists of five approved biologics, and the UC market consists of four; the most recent agent—Takeda’s Entyvio (vedolizumab; CD and UC)—received FDA approval in May 2014. In both CD and UC, Janssen’s Remicade (infliximab) continues to lead the U.S. market in sales and patient share as the therapy to beat for agents targeting patients refractory to conventional, less-costly agents, followed by AbbVie’s Humira (adalimumab). Despite the positive impact of these TNF-α inhibitors on CD and UC treatment, U.S. gastroenterologists indicate that novel agents are still needed that offer the basic clinical attributes of inducing and maintaining clinical remission at higher rates. With the recent launch of Entyvio and the anticipated launches of Janssen’s Stelara (ustekinumab) for CD and Pfizer’s Xeljanz (tofacitinib) for UC in the near future, the competitive environment will intensify, presenting physicians with additional therapy options for moderate-to-severe disease.

In this report, we gauge physicians’ and payers’ opinions of current biologics and emerging therapies for CD and UC to anticipate potential changes in the prescribing patterns and reimbursement climate. We focus on the available TNF-α inhibitors Remicade, Humira, Janssen’s Simponi (golimumab), and UCB’s Cimzia (certolizumab pegol); the cell adhesion molecule inhibitors Biogen Idec’s Tysabri (natalizumab) and Entyvio; and the emerging therapies Stelara and Xeljanz. In addition, we discuss physicians’ and payers’ opinions of biosimilars for infliximab and adalimumab, which we anticipate will launch during the same time frame as the branded agents, and how they will affect potential patient share of currently available and emerging therapies.

Related Market Assessment Reports

Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Primary Biliary Cholangitis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease, characterized by inflammation and progressive damage leading to destruction of interlobular bile ducts, followed by cholestasis…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…
Report
Schizophrenia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Schizophrenia (US)
Schizophrenia is a highly drug-treated condition that uses an array of medications, including atypical and typical antipsychotics, resulting in a complex treatment algorithm. Although this drug…